{"id":"valsartan-capsules","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"3-5","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"5-8","effect":"Headache"},{"rate":"2-4","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1069","moleculeType":"Small molecule","molecularWeight":"435.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in reduced blood pressure and improved cardiac function.","oneSentence":"Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:07.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction left ventricular dysfunction"}]},"trialDetails":[{"nctId":"NCT07465653","phase":"PHASE1","title":"A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-19","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":12},{"nctId":"NCT07356388","phase":"PHASE3","title":"FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan","status":"ACTIVE_NOT_RECRUITING","sponsor":"kewen Chen,MD","startDate":"2025-01-30","conditions":"Kidney Transplantation Recipients, Proteinuria Patients","enrollment":54},{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT06029712","phase":"PHASE2","title":"Heart Failure Polypill at a Safety Net Hospital","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2024-02-27","conditions":"Heart Failure With Reduced Ejection Fraction, HIV Infections","enrollment":35},{"nctId":"NCT03744975","phase":"PHASE2","title":"PDD in Type 2 Diabetes w/wo Diastolic Dysfunction","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Diastolic Dysfunction","enrollment":72},{"nctId":"NCT03785405","phase":"PHASE3","title":"Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-02","conditions":"Heart Failure","enrollment":216},{"nctId":"NCT06053580","phase":"PHASE2","title":"Repurposing Valsartan May Protect Against Pulmonary Hypertension","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-02-28","conditions":"Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction","enrollment":60},{"nctId":"NCT05593575","phase":"PHASE2","title":"Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-03-22","conditions":"Diabetic Kidney Disease","enrollment":305},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT04263922","phase":"PHASE4","title":"Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2020-06-30","conditions":"Renal Insufficiency, Chronic","enrollment":466},{"nctId":"NCT05095922","phase":"PHASE4","title":"Effect of HMP on Diabetic Microangiopaemia in T2DM","status":"COMPLETED","sponsor":"Affiliated Hospital of Nantong University","startDate":"2023-03-28","conditions":"Diabetes Mellitus, Type 2, Diabetic Angiopathies","enrollment":40},{"nctId":"NCT05359068","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2021-06-10","conditions":"Essential Hypertension","enrollment":957},{"nctId":"NCT00097786","phase":"PHASE3","title":"Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-01","conditions":"Diabetes Mellitus, Type 2","enrollment":9306},{"nctId":"NCT02924727","phase":"PHASE3","title":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-09","conditions":"Acute Myocardial Infarction","enrollment":5669},{"nctId":"NCT02678312","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-03","conditions":"Pediatric Heart Failure","enrollment":393},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT04859452","phase":"PHASE1","title":"A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-05-26","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT04623866","phase":"EARLY_PHASE1","title":"Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules","status":"UNKNOWN","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2020-11-01","conditions":"Henoch Schönlein Purpura Nephritis","enrollment":10},{"nctId":"NCT02480764","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-27","conditions":"Essential Hypertension","enrollment":612},{"nctId":"NCT02639637","phase":"PHASE4","title":"Effect of DPP4 Inhibition on Vasoconstriction","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT00439738","phase":"PHASE4","title":"Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Hypertension","enrollment":412},{"nctId":"NCT01785472","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":1438},{"nctId":"NCT02966717","phase":"PHASE2","title":"Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2016-08","conditions":"Renal Insufficiency, Chronic, Nephrotic Syndrome","enrollment":116},{"nctId":"NCT01672476","phase":"PHASE3","title":"A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2012-04","conditions":"Hypertension","enrollment":293},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01876368","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09","conditions":"Hypertension","enrollment":376},{"nctId":"NCT01615198","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":588},{"nctId":"NCT01599104","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Essential Hypertension","enrollment":1161},{"nctId":"NCT00549770","phase":"PHASE2","title":"Efficacy and Safety of LCZ696A in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-09","conditions":"Hypertension","enrollment":1334},{"nctId":"NCT00437645","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1183},{"nctId":"NCT01878201","phase":"PHASE2","title":"A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2013-05","conditions":"Essential Hypertension","enrollment":75},{"nctId":"NCT01415505","phase":"PHASE3","title":"Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-08","conditions":"Hypertension","enrollment":812},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT00927394","phase":"PHASE4","title":"Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-05","conditions":"Hypertension","enrollment":1143},{"nctId":"NCT00819767","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-02","conditions":"Hypertension","enrollment":68},{"nctId":"NCT01375322","phase":"PHASE4","title":"ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria","status":"COMPLETED","sponsor":"TSH Biopharm Corporation Limited","startDate":"2007-06","conditions":"Hypertension, Diabetes Mellitus, Type 2, Albuminuria","enrollment":226},{"nctId":"NCT00699192","phase":"PHASE3","title":"Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-05","conditions":"Hypertension","enrollment":965},{"nctId":"NCT01001572","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Essential Hypertension","enrollment":932},{"nctId":"NCT00700271","phase":"PHASE4","title":"Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Hypertension","enrollment":478},{"nctId":"NCT00425373","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Essential Hypertension","enrollment":1474},{"nctId":"NCT00413049","phase":"PHASE3","title":"Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Hypertension","enrollment":698},{"nctId":"NCT00413413","phase":"PHASE3","title":"Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Hypertension","enrollment":1134},{"nctId":"NCT00409578","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Post Acute Coronary Syndrome, Myocardial Ischemia","enrollment":1101},{"nctId":"NCT00698646","phase":"PHASE4","title":"Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Hypertension","enrollment":384},{"nctId":"NCT00687973","phase":"PHASE4","title":"Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-01","conditions":"Hypertension","enrollment":393},{"nctId":"NCT00931710","phase":"PHASE4","title":"Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Stage 2 Systolic Hypertension","enrollment":488}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"GASTROINTESTINAL HAEMORRHAGE"},{"count":2,"reaction":"MUSCULAR WEAKNESS"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"AGRANULOCYTOSIS"},{"count":1,"reaction":"ANGIOEDEMA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"AZOTAEMIA"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valsartan Capsules，National Medicine Permission Number H20040217，86900100000095"],"phase":"marketed","status":"active","brandName":"Valsartan Capsules","genericName":"Valsartan Capsules","companyName":"Affiliated Hospital of Nantong University","companyId":"affiliated-hospital-of-nantong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan Capsules are a small molecule that acts as a Type-1 angiotensin II receptor antagonist. They are used to treat conditions such as hypertension, diabetes-related complications, and heart failure, as well as to evaluate arterial stiffness in elderly patients with hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}